| Name | WRG-28 |
| Description | WRG-28 is a potent and selective, allosteric discoidin domain receptor 2 (ddr2) inhibitor(IC50 : 230 nM) |
| In vitro | WRG-28 is a selective, extracellularly acting small molecule inhibitor of DDR2 that uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor.?By targeting DDR2, WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.44 mM), Sonication is recommended.
DMSO : 15 mg/mL (36.55 mM), Sonication is recommended.
|
| Keywords | WRG-28 | WRG28 | WRG 28 | rheumatoid arthritis | joint destruction | Inhibitor | inhibit | HEK293 | DiscoidinDomainReceptor(DDR) | DiscoidinDomainReceptor | Discoidin Domain Receptor (DDR) | Discoidin Domain Receptor | DDR2 | DDR | CAFs | BT549 | breast cancer | 4T1 breast cancer cells |
| Inhibitors Related | DDR-TRK-1 | DDR Inhibitor | VU6015929 | Ddr1-In-1 | DDR1-IN-4 | FGFR1/DDR2 inhibitor 1 | Sitravatinib | LCB 03-0110 | Merestinib | DDR1-IN-2 | GLPG3312 | (S)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
